Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer

Phase 2 pilot PANOVA data presented at the American Association for Cancer Research Annual Meeting 2017 Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today results …

Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer

Phase 2 pilot INNOVATE data will be presented at the American Association for Cancer Research Annual Meeting 2017 Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today results from its phase 2 …

Novocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with Standard of Care Chemotherapy in Mesothelioma

Interim results from the STELLAR trial, presented in December 2016, suggest improvements in progression free survival and one-year survival rates when TTFields is added to standard chemotherapy ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the STELLAR trial, a phase 2 pilot trial testing Tumor Treating Fields (TTFields) …

Novocure to Report First Quarter 2017 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2017 on Thursday, April 27, 2017, before the U.S.-based financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2017, at 8 …

Novocure to Present at the 16th Annual Needham & Company Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the 16th Annual Needham & Company Healthcare Conference on April 5, 2016, in New York. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s presentation will begin at 4:20 p.m. EST and …

Novocure Receives MHLW Approval for Second Generation Optune® in Japan

Second generation Optune is now approved in all active Novocure markets Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has …

Novocure Announces Data Presentations at the American Association for Cancer Research Annual Meeting 2017

Five-year survival analysis from the EF-14 phase 3 pivotal trial evaluating TTFields in combination with temozolomide for newly diagnosed glioblastoma to be shared in an oral presentation PANOVA clinical data to be presented evaluating TTFields in combination with standard chemotherapy for advanced pancreatic cancer INNOVATE clinical data to be presented evaluating TTFields in combination with …